Mometasone furoate · MOMETASONE FUROATE 1 mg/g · Ointment · Topical · Glenmark Pharmaceuticals Inc., USA
NDC 68462-0225-17 · 15 g in 1 TUBE · ANDA · View full market →
10 companies supply this market — deep enough that no single failure threatens the supply. The price is down 23% over the past year, to $0.3420 per unit.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Matched to CMS's representative package for this drug (NDC 45802-0119-42) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 9 quarters since 2024.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Not scored — fragility is computed for NADAC-priced NDCs.
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| A-S Medication Solutions | MOMETASONE FUROATE 1 mg/g | Jul 15, 2026 | Sep 2, 2026 |
| Cosette Pharmaceuticals, Inc. | MOMETASONE FUROATE 1 mg/g | Jul 15, 2026 | Sep 2, 2026 |
| Encube Ethicals, Inc. | MOMETASONE FUROATE 1 mg/g | Jul 15, 2026 | Sep 2, 2026 |
| Padagis Israel Pharmaceuticals Ltd | MOMETASONE FUROATE 1 mg/g | Jul 15, 2026 | Sep 2, 2026 |
| Preferred Pharmaceuticals Inc. | MOMETASONE FUROATE 1 mg/g | Jul 15, 2026 | Sep 2, 2026 |
| Proficient Rx LP | MOMETASONE FUROATE 1 mg/g | Jul 15, 2026 | Sep 2, 2026 |
| Sportpharm LLC | MOMETASONE FUROATE 1 mg/g | Jul 15, 2026 | Sep 2, 2026 |
| Torrent Pharmaceuticals Limited | MOMETASONE FUROATE 1 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Bryant Ranch Prepack | MOMETASONE FUROATE 1 mg/g | Jul 15, 2026 | Aug 31, 2026 |
| Glenmark Pharmaceuticals Inc., USA | MOMETASONE FUROATE 1 mg/g | Jul 15, 2026 | Aug 5, 2026 |
| Sun Pharmaceutical Industries, Inc. | MOMETASONE FUROATE 1 mg/g | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Mometasone Furoate — NDC 68462-0225-17," retrieved September 3, 2026, https://drugdashboards.com/drug/68462022517.
Free to cite with attribution — see how the data is put together.